This new vaccine is targeting mammaglobin-A, a protein found almost exclusively in breast tissue, destroying the cells containing it.“In theory, this means we could treat a large number of breast cancer patients with potentially fewer side effects,” said to media William E. Gillanders, senior study author and breast cancer surgeon. The side effects observed during the clinical trial were considered mild or moderate. As final effect, the vaccine slowed the cancer progression even in patients who had less potent immune systems. “That’s very encouraging. We also saw preliminary evidence of improved outcome, with modestly longer progression-free survival,” the authors of the study appreciated. A future larger clinical trial is planned now to test the effect of the vaccine in newly diagnosed breast cancer patients. The new therapy should be considered soon to help patients with cancer.